CXCR4 antagonists suppress small cell lung cancer progression
- PMID: 27835905
- PMCID: PMC5356728
- DOI: 10.18632/oncotarget.13238
CXCR4 antagonists suppress small cell lung cancer progression
Abstract
Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis due to early metastatic spread and development of chemoresistance. Playing a key role in tumor-stroma interactions the CXCL12-CXCR4 axis may be involved in both processes and thus represent a promising therapeutic target in SCLC treatment. In this study we investigated the effect of CXCR4 inhibition on metastasis formation and chemoresistance using an orthotopic xenograft mouse model. This model demonstrates regional spread and spontaneous distant metastases closely reflecting the clinical situation in extensive SCLC. Tumor engraftment, growth, metabolism, and metastatic spread were monitored using different imaging techniques: Magnetic Resonance Imaging (MRI), Bioluminescence Imaging (BLI) and Positron Emission Tomography (PET). Treatment of mice bearing chemoresistant primary tumors with the specific CXCR4 inhibitor AMD3100 reduced the growth of the primary tumor by 61% (P<0.05) and additionally suppressed metastasis formation by 43%. In comparison to CXCR4 inhibition as a monotherapy, standard chemotherapy composed of cisplatin and etoposide reduced the growth of the primary tumor by 71% (P<0.01) but completely failed to suppress metastasis formation. Combination of chemotherapy and the CXCR4 inhibitor integrated the highest of both effects. The growth of the primary tumor was reduced to a similar extent as with chemotherapy alone and metastasis formation was reduced to a similar extent as with CXCR4 inhibitor alone. In conclusion, we demonstrate in this orthotopic mouse model that the addition of a CXCR4 inhibitor to chemotherapy significantly reduces metastasis formation. Thus, it might improve the overall therapy response and consequently the outcome of SCLC patients.
Keywords: AMD3100; CXCL12; metastasis; mouse model; small cell lung cancer.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356728/bin/oncotarget-07-85185-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356728/bin/oncotarget-07-85185-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356728/bin/oncotarget-07-85185-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356728/bin/oncotarget-07-85185-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5356728/bin/oncotarget-07-85185-g005.gif)
Similar articles
-
A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.Mol Ther. 2021 Oct 6;29(10):2963-2978. doi: 10.1016/j.ymthe.2021.05.014. Epub 2021 May 21. Mol Ther. 2021. PMID: 34023505 Free PMC article.
-
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.Clin Exp Metastasis. 2016 Oct;33(7):651-60. doi: 10.1007/s10585-016-9808-8. Epub 2016 Jul 6. Clin Exp Metastasis. 2016. PMID: 27380917
-
Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.FEBS Lett. 2012 Oct 19;586(20):3639-44. doi: 10.1016/j.febslet.2012.08.011. Epub 2012 Aug 28. FEBS Lett. 2012. PMID: 22992418
-
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30. doi: 10.1586/era.11.11. Expert Rev Anticancer Ther. 2011. PMID: 21504328 Review.
-
CXCR4 chemokine receptor antagonists: perspectives in SCLC.Expert Opin Investig Drugs. 2009 Apr;18(4):481-90. doi: 10.1517/13543780902804249. Expert Opin Investig Drugs. 2009. PMID: 19335276 Review.
Cited by
-
Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.Int J Mol Sci. 2024 Apr 7;25(7):4102. doi: 10.3390/ijms25074102. Int J Mol Sci. 2024. PMID: 38612911 Free PMC article. Review.
-
The β2-adrenergic receptor associates with CXCR4 multimers in human cancer cells.Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2304897121. doi: 10.1073/pnas.2304897121. Epub 2024 Mar 28. Proc Natl Acad Sci U S A. 2024. PMID: 38547061
-
Tumor-associated macrophages: an effective player of the tumor microenvironment.Front Immunol. 2023 Nov 16;14:1295257. doi: 10.3389/fimmu.2023.1295257. eCollection 2023. Front Immunol. 2023. PMID: 38035101 Free PMC article. Review.
-
Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas.Int J Mol Sci. 2022 Dec 28;24(1):478. doi: 10.3390/ijms24010478. Int J Mol Sci. 2022. PMID: 36613922 Free PMC article. Review.
-
Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response.Semin Cancer Biol. 2022 Dec;87:117-126. doi: 10.1016/j.semcancer.2022.11.005. Epub 2022 Nov 9. Semin Cancer Biol. 2022. PMID: 36371025 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69–90. - PubMed
-
- Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. Journal of the National Comprehensive Cancer Network. 2013;11:99–104. - PubMed
-
- Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. The oncologist. 2009;14:986–994. - PubMed
-
- Balkwill F. Cancer and the chemokine network. Nature reviews Cancer. 2004;4:540–550. - PubMed
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical